EXOZ Stock Forecast: eXoZymes, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores eXoZymes, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
EXOZ stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EXOZ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
EXOZ appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
EXOZ vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, eXoZymes, Inc. returned −81.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
EXOZ analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 12.3×
- EV / EBITDA
- —
Cheaper than 6% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −268.1%
- Return on assets
- −102.0%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
eXoZymes, Inc. has a market value of $27.4M and an enterprise value of $25.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$10.2M.
Free cash flow in the twelve months to 30 June 2026: −$7.1M.
eXoZymes, Inc. employs 32 people.
Data provided by Twelve Data
EXOZ and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at EXOZ’s peer groups, ranked by the model: materials stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own eXoZymes, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about EXOZ
How does Ticker Nerd's model rank EXOZ?
As at 21 Nov 2026, eXoZymes, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).
What is the EXOZ stock forecast for 2030?
No analyst covering eXoZymes, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EXOZ are extrapolating price history, which says nothing about the business.
How has EXOZ stock performed over the past year?
eXoZymes, Inc. returned -81.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does eXoZymes, Inc. do?
eXoZymes Inc. is a biotechnology company focused on cell-free biomanufacturing platforms that use AI-enhanced enzymes to produce complex molecules outside living cells. The company’s technology is designed to convert affordable feedstocks into high-purity chemicals that are difficult, costly, or inefficient to make through conventional methods.
About eXoZymes, Inc.
eXoZymes Inc. is a biotechnology company focused on cell-free biomanufacturing platforms that use AI-enhanced enzymes to produce complex molecules outside living cells. The company’s technology is designed to convert affordable feedstocks into high-purity chemicals that are difficult, costly, or inefficient to make through conventional methods. Its current work centers on developing enzyme modules and biocatalytic systems for applications in pharmaceuticals, nutraceuticals, biofuels, and specialty chemicals. By combining synthetic biology, enzyme engineering, and bioreactor-based production, eXoZymes serves markets that require scalable, precise, and adaptable manufacturing solutions. Headquartered in Monrovia, California, eXoZymes positions itself at the intersection of biotechnology and industrial chemistry, supporting the production of valuable molecules used across health, energy, and materials sectors.
CEO Mr. Michael Heltzen · 32 employees · United States · https://www.exozymes.com